SCHEDULES

SCHEDULE 4

Standard provisions of licences under Part 3

PART 2

Manufacturer's licence relating to the import of medicinal products from a state other than an EEA State **[**[F1]/ Country other than an Approved Country for Import**]**

Textual Amendments

F1 Words in Sch. 4 Pt. 2 heading inserted (31.12.2020) by S.I. 2019/775, regs. 1, **20(3)** (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, **Sch. 2 para. 14(c)**)

[[F1]**23ZA.** The licence holder in Great Britain must take all reasonable precautions and exercise due diligence to ensure that any information provided to the licensing authority which is relevant to an evaluation of the safety, quality or efficacy of a product for human use which is supplied from Great Britain into Northern Ireland by virtue of regulation 167A handled, stored or distributed under the licence is not false or misleading in a material particular.**]**

Textual Amendments

F1 Sch. 4 para. 23ZA inserted (1.1.2022) by The Human Medicines (Amendment) (Supply to Northern Ireland) Regulations 2021 (S.I. 2021/1452), regs. 1(2), **25**

Changes to legislation:
There are currently no known outstanding effects for the The Human Medicines Regulations 2012, Paragraph 23ZA.